MarginsXMarginsX
Home › Markets › Health Care › ABBV

AbbVie Inc. (ABBV)

ABBV trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$294.55
-0.16% on the day
Market cap
$520.7B
Mega cap
Revenue · 2025
$61.2B
+8.6% on 2024
Net income · 2025
$4.2B
6.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerABBV on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2012
SEC CIK0001551152
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$61.2B
Net income$4.2B
Operating income$15.1B
Net margin6.9%
Operating margin24.6%
Revenue growth+8.6%
Cash$5.2B
Total assets$134.0B
P/E (computed)123.2×
P/S (computed)8.5×

Warning signs

Cash runway
Cash-flow positive
$10.8B cash at September 30, 2026
Share count, 1 year
0.0%
2025-10-27 to 2026-10-26 · +0.1% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$18.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$10.8B cash; operating cash flow $5.0B a quarter.Report 2026-09-30
Shares outstanding1,767,616,306 (2026-10-26); 1,767,384,632 a year earlier; 1,765,537,421 three years earlier.Cover page 2026-10-26
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 4 424B5 takedownsLatest 2026-08-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Chicago, Illinois, United StatesPCAOB Form AP 2026-03-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $18.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$17.4B$4.2B$7.6B$10.8B$80.9B$66.0B10-Q 2026-11-03
Q2 2026
2026-06-30
$17.0B$3.6B$3.4B$6.6B$70.8B$64.4B10-Q 2026-08-03
Q1 2026
2026-03-31
$15.0B$695.0M$3.8B$9.4B$72.9B$62.8B10-Q 2026-05-08
Q4 2025
2025-12-31
$16.6B$1.8B$5.2B$5.2B$67.0B$61.2B10-K 2026-02-20
Q3 2025
2025-09-30
$15.8B$186.0M$7.0B$5.6B$68.7B$59.6B10-Q 2026-11-03
Q2 2025
2025-06-30
$15.4B$938.0M$5.2B$6.5B$70.5B$58.3B10-Q 2026-08-03
Q1 2025
2025-03-31
$13.3B$1.3B$1.6B$5.2B$69.9B$57.4B10-Q 2026-05-08
Q4 2024
2024-12-31
$15.1B-$22.0M$7.0B$5.5B$66.8B$56.3B10-K 2025-02-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-06
Latest annual report10-K2026-02-20
Latest quarterly / interim10-Q2026-11-03
Latest current report
FORM 8-K
8-K2026-11-02
Latest proxyDEFA14A2026-03-23

Source: SEC EDGAR submissions feed, 1,008 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.3%
1 month+7.5%
3 months+17.6%
Year to date+29.1%
1 year+27.0%
From 52-week high0.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
JNJJohnson & Johnson$282.55-1.12%$680.2B
MRKMerck & Company Inc. Common Stock (new)$144.46-2.23%$356.1B
NVSNovartis AG$160.20-0.19%$305.7B
AZNAstraZeneca PLC$184.02-0.23%$285.4B
LLYEli Lilly and Company$1431.67-0.82%$1.35T
ABTAbbott Laboratories$107.45-0.99%$186.1B
NVONovo Nordisk A/S$41.60-0.07%$184.2B
PFEPfizer Inc.$28.86-0.10%$164.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier